As the linked article doesn't name the paper, here's a link to it:
Title: Direct detection of early-stage cancers using circulating tumor DNA
Link (no paywall): http://stm.sciencemag.org/content/9/403/eaan2415
Title: Direct detection of early-stage cancers using circulating tumor DNA
Link (no paywall): http://stm.sciencemag.org/content/9/403/eaan2415
Figure 2 shows the sequencing error rate reduced from around 1e-4 using conventional NGS to 1e-6 using TEC-Seq.
This increased sensitivity allows for discovery of early cancer at levels that are undetectable using existing cfDNA testing techniques.
Targeted capture using Agilent's SureSelect is pretty common in the cancer field. Their custom implementation allows for oversampling (30,000x) which, along the enzymatic error correction, allows them a high confidence in the target they chose to evaluate.
Overall, I think this is neat.